Artigos de revistas sobre o tema "Metastatic papillary renal-Cell cancer"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Metastatic papillary renal-Cell cancer".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Sidana, Abhinav, Amit L. Jain, Meet Kadakia, Spencer Krane, Julia C. Friend, Akhil Muthigi, Martha Ninos, Joanna H. Shih e Ramaprasad Srinivasan. "Predictors of mortality in metastatic papillary renal cell cancer." Journal of Clinical Oncology 35, n.º 6_suppl (20 de fevereiro de 2017): 509. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.509.
Texto completo da fonteCarlo, Maria Isabel, Nabeela Khan, Yingbei Chen, James Hsieh, A. Ari Hakimi, Chung-Han Lee, Darren R. Feldman, Robert J. Motzer e Martin Henner Voss. "The genomic landscape of metastatic non-clear cell renal cell carcinoma." Journal of Clinical Oncology 35, n.º 6_suppl (20 de fevereiro de 2017): 474. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.474.
Texto completo da fonteGraham, Jeffrey, Connor Wells, Frede Donskov, Jae-Lyun Lee, Anna Paola Fraccon, Felice Pasini, Camillo Porta et al. "Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)." Journal of Clinical Oncology 36, n.º 6_suppl (20 de fevereiro de 2018): 581. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.581.
Texto completo da fonteDudani, Shaan, Guillermo de Velasco, Connor Wells, Chun Loo Gan, Frede Donskov, Camillo Porta, Anna Fraccon et al. "Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma." Journal of Clinical Oncology 38, n.º 15_suppl (20 de maio de 2020): 5071. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5071.
Texto completo da fonteMotzer, Robert J., Jennifer Bacik, Tania Mariani, Paul Russo, Madhu Mazumdar e Victor Reuter. "Treatment Outcome and Survival Associated With Metastatic Renal Cell Carcinoma of Non–Clear-Cell Histology". Journal of Clinical Oncology 20, n.º 9 (1 de maio de 2002): 2376–81. http://dx.doi.org/10.1200/jco.2002.11.123.
Texto completo da fonteRonnen, Ellen A., G. Varuni Kondagunta, Nicole Ishill, Lesley Spodek, Paul Russo, Victor Reuter, Jennifer Bacik e Robert J. Motzer. "Treatment outcome for metastatic papillary renal cell carcinoma patients". Cancer 107, n.º 11 (2006): 2617–21. http://dx.doi.org/10.1002/cncr.22340.
Texto completo da fonteElabbady, Ahmed, Ryan Boudreau e Vahid Mehrnoush. "Rapid metachronous bladder metastasis of type 2 papillary renal cell carcinoma". Archive of Clinical Cases 10, n.º 2 (18 de maio de 2023): 93–96. http://dx.doi.org/10.22551/2023.39.1002.10249.
Texto completo da fonteSteiner, T., J. Roigas, H. Kirchner, C. Doehn, H. Heynemann, M. Siebels, S. Loening et al. "Clinical course of patients with metastatic papillary renal cell carcinoma". Journal of Clinical Oncology 24, n.º 18_suppl (20 de junho de 2006): 14591. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.14591.
Texto completo da fonteYonese, Ichiro, Masaya Ito, Kosuke Takemura, Takao Kamai e Fumitaka Koga. "A Case of Metastatic Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome-Associated Renal Cell Carcinoma Treated with a Sequence of Axitinib and Nivolumab Following Cytoreductive Nephrectomy". Journal of Kidney Cancer and VHL 7, n.º 2 (20 de julho de 2020): 6–10. http://dx.doi.org/10.15586/jkcvhl.2020.148.
Texto completo da fonteSchrader, A. J., S. Rauer-Bruening, P. J. Olbert, A. Hegele, J. Rustemeier e R. Hofmann. "Incidence and long term prognosis of papillary renal cell carcinoma". Journal of Clinical Oncology 27, n.º 15_suppl (20 de maio de 2009): e16020-e16020. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e16020.
Texto completo da fonteFriend, Julia C., Daniel Su, Rashmi Thimmapuram, James Peterson, Geri Hawks, Martha Ninos, W. Marston Linehan e Ramaprasad Srinivasan. "Malignant ascites as a manifestation of advanced papillary renal cell cancer (pRCC)." Journal of Clinical Oncology 33, n.º 7_suppl (1 de março de 2015): 465. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.465.
Texto completo da fonteWells, J. Connor, Frede Donskov, Anna Paola Fraccon, Felice Pasini, Georg A. Bjarnason, Jennifer J. Knox, Benoit Beuselinck et al. "Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC)." Journal of Clinical Oncology 34, n.º 15_suppl (20 de maio de 2016): 4554. http://dx.doi.org/10.1200/jco.2016.34.15_suppl.4554.
Texto completo da fonteSomorácz, Áron, Levente Kuthi, Tamás Micsik, Alex Jenei, Adrienn Hajdu, Brigitta Vrabély, Erzsébet Rásó et al. "Renal Cell Carcinoma with Clear Cell Papillary Features: Perspectives of a Differential Diagnosis". Pathology & Oncology Research 26, n.º 3 (26 de outubro de 2019): 1767–76. http://dx.doi.org/10.1007/s12253-019-00757-3.
Texto completo da fonteBarua, Sasanka K., Sarbartha K. Pratihar, Pranab K. Kaman, Atul Garg, Rajeev T. P., Saumar J. Baruah, Puskal K. Bagchi, Debanga Sarma e Mandeep Phukan. "Cervical lymphadenopathy as initial presentation of genito-urinary cancer". International Journal of Otorhinolaryngology and Head and Neck Surgery 5, n.º 6 (23 de outubro de 2019): 1739. http://dx.doi.org/10.18203/issn.2454-5929.ijohns20194964.
Texto completo da fonteStenman, Maria, Andreas Demetrios Nearchou, Per Sandström, Magnus Lindskog e Ulrika Harmenberg. "Metastatic papillary renal cell carcinoma: A retrospective study from two large academic centers in Sweden." Journal of Clinical Oncology 34, n.º 2_suppl (10 de janeiro de 2016): 535. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.535.
Texto completo da fontePark, Sang Hyun, Taek Sang Kim, Jae Young Joung, Sung Han Kim e Jinsoo Chung. "Postoperative long-term prognosis of localized renal cell carcinoma after partial or radical nephrectomy: Analysis of cancer metastasis and deaths during a more than five-year follow-up." Journal of Clinical Oncology 37, n.º 7_suppl (1 de março de 2019): 604. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.604.
Texto completo da fonteZielli, Teresa, Letizia Gnetti e Sebastiano Buti. "Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report". Tumori Journal 106, n.º 6 (27 de maio de 2020): NP79—NP83. http://dx.doi.org/10.1177/0300891620924472.
Texto completo da fonteArmstrong, Andrew J., Susan Halabi, Tim Eisen, Walter Michael Stadler, Robert R. Jones, Ulka N. Vaishampayan, Jorge A. Garcia et al. "ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma." Journal of Clinical Oncology 31, n.º 15_suppl (20 de maio de 2013): TPS4590. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.tps4590.
Texto completo da fonteShuch, Brian, Lambros Stamatakis, Clara Chen, Rabindra Gautam, Maria Merino, Peter L. Choyke, W. Marston Linehan e Ramaprasad Srinivasan. "Utility of 2-(18F) fluoro-2 deoxy-D-glucose PET/CT in advanced papillary renal cell carcinoma." Journal of Clinical Oncology 32, n.º 4_suppl (1 de fevereiro de 2014): 419. http://dx.doi.org/10.1200/jco.2014.32.4_suppl.419.
Texto completo da fonteDidwaniya, N., R. J. Edmonds, X. Fang, P. T. Silberstein e S. Subbiah. "Survival outcomes in metastatic renal carcinoma based on histological subtypes: SEER database analysis." Journal of Clinical Oncology 29, n.º 7_suppl (1 de março de 2011): 381. http://dx.doi.org/10.1200/jco.2011.29.7_suppl.381.
Texto completo da fontede Vries-Brilland, Manon, Nathalie Rioux-Leclercq, Maxime Meylan, Jonathan Dauvé, Christophe Passot, Elena Spirina-Menand, Ronan Flippot et al. "Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma". Journal for ImmunoTherapy of Cancer 11, n.º 11 (novembro de 2023): e006885. http://dx.doi.org/10.1136/jitc-2023-006885.
Texto completo da fonteMcKay, Rana R., Pedro C. Barata, Andrew Elliott, Mehmet Asim Bilen, Earle F. Burgess, Sourat Darabi, Nancy Ann Dawson et al. "Molecular alterations across sites of metastasis in patients with renal cell carcinoma (RCC)." Journal of Clinical Oncology 40, n.º 6_suppl (20 de fevereiro de 2022): 287. http://dx.doi.org/10.1200/jco.2022.40.6_suppl.287.
Texto completo da fonteBambury, Richard Martin, Claire Brady, Aoife McCarthy, Stewart Fleming, Nicholas J. Mayer e Derek Gerard Power. "Translocation renal cell carcinomas: An evolving entity." Journal of Clinical Oncology 30, n.º 5_suppl (10 de fevereiro de 2012): 472. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.472.
Texto completo da fonteEldessouki, Ihab, Ola Gaber, Mahmoud A. Shehata, Tariq Namad, Joseph Atallah, Harsha Masineni e Nagla Abdel Karim. "Papillary renal cell carcinoma: what is missing in research? A case report and a review of literature". SAGE Open Medical Case Reports 7 (janeiro de 2019): 2050313X1986947. http://dx.doi.org/10.1177/2050313x19869475.
Texto completo da fonteSu, Daniel, Chinonyerem Okoro, Arvin George, W. Marston Linehan e Adam R. Metwalli. "Bilateral multifocal papillary type I renal cell carcinoma: Clinical characteristics and association with chronic renal insufficiency." Journal of Clinical Oncology 32, n.º 4_suppl (1 de fevereiro de 2014): 482. http://dx.doi.org/10.1200/jco.2014.32.4_suppl.482.
Texto completo da fonteAgarwala, Vivek, Anant Ramaswamy, Amit Joshi, Vijay Maruti Patil, Vanita Noronha, Santosh Menon, B. Palak Popat, Sable Nilesh e Kumar Prabhash. "Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis". South Asian Journal of Cancer 07, n.º 04 (outubro de 2018): 226–30. http://dx.doi.org/10.4103/sajc.sajc_22_18.
Texto completo da fonteEssam, Abdul Monem, Ajit Venniyoor, Suresh Nagdev, Itrat Mehdi e Bassim Al Bahrani. "Long-term survival in a case of metastatic papillary renal cell carcinoma". South Asian Journal of Cancer 06, n.º 01 (janeiro de 2017): 019–34. http://dx.doi.org/10.4103/2278-330x.202562.
Texto completo da fonteYamazaki, Haruhiko, Takeshi Kishida, Go Noguchi, Hiroyuki Iwasaki, Nobuyasu Suganuma, Katsuhiko Masudo, Hirotaka Nakayama et al. "Nephrectomy for Metastatic Kidney Tumor in Patients with Differentiated Thyroid Cancer: A Report of Two Cases". Case Reports in Endocrinology 2018 (11 de novembro de 2018): 1–5. http://dx.doi.org/10.1155/2018/7842792.
Texto completo da fonteVoss, Martin Henner, Yingbei Chen, Joshua Chaim, Devyn Taylor Coskey, Kaitlin Woo, Sujata Patil, Ana M. Molina, James Hsieh, Robert J. Motzer e Darren Richard Feldman. "A phase II trial of everolimus and bevacizumab in advanced non-clear cell renal cell cancer." Journal of Clinical Oncology 33, n.º 7_suppl (1 de março de 2015): 411. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.411.
Texto completo da fonteLam, J. S., R. H. Goel, A. J. Pantuck, R. A. Figlin e A. S. Belldegrun. "Long-term survival following nephrectomy for renal cell carcinoma: The 15 year University of California-Los Angeles experience". Journal of Clinical Oncology 24, n.º 18_suppl (20 de junho de 2006): 14532. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.14532.
Texto completo da fontePeters, Inga, Christel Reese, Natalia Dubrowinskaja, Wiebke Inga Antonopoulos, Martin Krause, Tu Nghi Dang, Alexander Grote et al. "DNA methylation signature for the assessment of metastatic risk in primary renal cell cancer." Journal of Clinical Oncology 35, n.º 6_suppl (20 de fevereiro de 2017): 516. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.516.
Texto completo da fonteChoueiri, Toni K., Anne Plantade, Paul Elson, Sylvie Negrier, Alain Ravaud, Stephane Oudard, Ming Zhou, Brian I. Rini, Ronald M. Bukowski e Bernard Escudier. "Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma". Journal of Clinical Oncology 26, n.º 1 (1 de janeiro de 2008): 127–31. http://dx.doi.org/10.1200/jco.2007.13.3223.
Texto completo da fonteVoss, Martin H., Ana M. Molina, Ying-Bei Chen, Kaitlin M. Woo, Joshua L. Chaim, Devyn T. Coskey, Almedina Redzematovic et al. "Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non–Clear Cell Renal Cell Carcinoma". Journal of Clinical Oncology 34, n.º 32 (10 de novembro de 2016): 3846–53. http://dx.doi.org/10.1200/jco.2016.67.9084.
Texto completo da fontePower, Derek Gerard, Jodie E. Battley, Aoife McCarthy, Claire Brady, John P. Sweeney, Stewart Fleming, Nicholas J. Mayer e Richard Martin Bambury. "Translocation renal cell carcinomas: An evolving entity." Journal of Clinical Oncology 30, n.º 15_suppl (20 de maio de 2012): e15078-e15078. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e15078.
Texto completo da fonteTsimafeyeu, Ilya, Alexandra Naumova, Evgenia Stepanova, Alfia Khasanova, Ilya Varlamov, Nigel Wynn, Anton Snegovoy e Lev V. Demidov. "FGFR2 expression to predict survival outcome in patients with metastatic papillary renal cell carcinoma." Journal of Clinical Oncology 34, n.º 2_suppl (10 de janeiro de 2016): 506. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.506.
Texto completo da fonteNicaise, Edouard, Benjamin Schmeusser, Adil Ali, Eric Midenberg, Arnold Raul Palacios, Ethan Kearns, Sriram Ambadi et al. "Linear muscle segmentation for metastatic renal cell carcinoma." Journal of Clinical Oncology 42, n.º 4_suppl (1 de fevereiro de 2024): 380. http://dx.doi.org/10.1200/jco.2024.42.4_suppl.380.
Texto completo da fonteMorinaga, Ryota, Takashi Kawahara, Yasuhide Miyoshi, Masahiro Yao e Hiroji Uemura. "Longer Control of Nivolumab in Metastatic Renal Cell Carcinoma Patients with End-Stage Kidney Disease on Dialysis". Case Reports in Oncology 12, n.º 2 (6 de agosto de 2019): 608–12. http://dx.doi.org/10.1159/000501768.
Texto completo da fonteAlbiges, Laurence, Daniel Yick Chin Heng, Jae-Lyun Lee, Stephen Walker, Anders Mellemgaard, Lone Ottesen, Melanie M. Frigault et al. "MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data." Journal of Clinical Oncology 38, n.º 15_suppl (20 de maio de 2020): e19321-e19321. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19321.
Texto completo da fonteMoreira, Raphael Brandao, Rana R. McKay, Wanling Xie, Daniel Yick Chin Heng, Guillermo de Velasco, Daniel E. Castellano, Andre Poisl Fay et al. "Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC)." Journal of Clinical Oncology 35, n.º 6_suppl (20 de fevereiro de 2017): 482. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.482.
Texto completo da fonteHeng, Daniel Y. C., e Toni K. Choueiri. "Non–Clear Cell Renal Cancer: Features and Medical Management". Journal of the National Comprehensive Cancer Network 7, n.º 6 (junho de 2009): 659–65. http://dx.doi.org/10.6004/jnccn.2009.0046.
Texto completo da fonteBodard, Sylvain, Idris Boudhabhay, Charles Dariane, Christophe Delavaud, Sylvain Guinebert, Dominique Joly, Marc-Olivier Timsit et al. "Percutaneous Thermal Ablation for Renal Tumors in Patients with Birt–Hogg–Dubé Syndrome". Cancers 14, n.º 20 (11 de outubro de 2022): 4969. http://dx.doi.org/10.3390/cancers14204969.
Texto completo da fontevon Klot, Christoph A. J., Natalia Dubrowinskaja, Jörg Hennenlotter, Mario W. Kramer, Axel S. Merseburger, Arnulf Stenzl, Inga Peters, Hossein Tezval, Markus A. Kuczyk e Juergen Serth. "Rho GDP dissociation inhibitor beta ARHGDIB in renal cell cancer." Journal of Clinical Oncology 33, n.º 7_suppl (1 de março de 2015): 474. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.474.
Texto completo da fonteTsimafeyeu, I., A. Khasanova, E. Stepanova, M. Gordiev, D. Khochenkov, A. Naumova, I. Varlamov, A. Snegovoy e L. Demidov. "FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma". Clinical and Translational Oncology 19, n.º 2 (5 de julho de 2016): 265–68. http://dx.doi.org/10.1007/s12094-016-1524-y.
Texto completo da fonteSawyer, Reed, e Harris Wayne B. "Clinical implications of epigenetics in Renal Cell Carcinoma". Archives of Renal Diseases and Management 7, n.º 1 (27 de julho de 2022): 008–13. http://dx.doi.org/10.17352/2455-5495.000040.
Texto completo da fonteMarchand Crety, Charles, Estelle Vigneau e Camille Invernizzi. "Stereotactic Body Radiotherapy of a Solitary Metachronous Sphenoid Metastasis from Renal Cell Cancer: A Case Report". Case Reports in Oncology 14, n.º 1 (2 de março de 2021): 269–73. http://dx.doi.org/10.1159/000513743.
Texto completo da fonteAhrens, Marit, Bernard Escudier, John B. A. G. Haanen, Ekaterini Boleti, Marine Gross Goupil, Marc-Oliver Grimm, Sylvie Negrier et al. "A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)." Journal of Clinical Oncology 39, n.º 15_suppl (20 de maio de 2021): TPS4597. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.tps4597.
Texto completo da fonteAhrens, Marit, Bernard Escudier, Ekaterini Boleti, Marc-Oliver Grimm, Marine Gross-Goupil, Philippe Barthelemy, Gwenaelle Gravis et al. "A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)." Journal of Clinical Oncology 38, n.º 15_suppl (20 de maio de 2020): TPS5103. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps5103.
Texto completo da fonteCasuscelli, Jozefina, Andrew G. Winer, Eduard Reznik, Jianing Xu, Brandon Manley, Jyoti Chouhan, Victor E. Reuter et al. "Single-institutional analysis of patients with clear-cell papillary renal cell carcinoma." Journal of Clinical Oncology 34, n.º 2_suppl (10 de janeiro de 2016): 512. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.512.
Texto completo da fonteGrenader, Tal, Eli Rosenbaum, Sofia Zilber, Naama Bogot e Linda Shavit. "Spontaneous Regression of Metastatic Papillary Renal Cell Cancer After Cessation of Treatment With Sorafenib". Clinical Genitourinary Cancer 11, n.º 2 (junho de 2013): 201–3. http://dx.doi.org/10.1016/j.clgc.2012.11.005.
Texto completo da fontePrager, Gerald, e Marina Poettler. "CD98hc expression to predict prognosis in renal cell cancer." Journal of Clinical Oncology 30, n.º 30_suppl (20 de outubro de 2012): 26. http://dx.doi.org/10.1200/jco.2012.30.30_suppl.26.
Texto completo da fonte